First-line IVF produced more live births than IUI within 7 months in couples with unexplained infertility.
|Podcasts|June 30, 2022
Managed Care Cast Presents: ILD Peer Exchange—Treatment Goals in ILD, Part 1
In part 1 of this 2-part podcast, a panel of experts discusses treatment goals in patients with interstitial lung disease (ILD) and reviews of treatment paradigms and standard of care therapies
Advertisement
Today we are bringing you part 1 of a 2-part sponsored podcast series discussing treatment goals in insterstitial lung disease (ILD). The discussion was moderated by Ryan Haumschild, PharmD, director of Pharmacy Services at Emory Healthcare and Winship Cancer Institute.
The topics of conversation for today’s podcast include treatment goals in patients with ILD and a review of treatment paradigms and standard of care therapies.
Advertisement
Related to this article
Elafibranor and seladelpar normalized ALP in most patients with primary biliary cholangitis whose ALP was below the usual escalation threshold.
The FDA granted accelerated approval to amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck cancer.
Most patients with MASH stay on resmetirom at 1 year, but Medicaid coverage was tied to lower odds of filling a first prescription within 30 days.
A 20-year review traces how immune checkpoint inhibitors became a cornerstone of lung cancer treatment.
David T. Plante, MD, PhD, explains that separating mood-related sleepiness from primary hypersomnia relies on the course of illness and sleep testing.
Six studies found liver transplant disparities by insurance, region, ethnicity, and sex, plus links between unmet social needs and frailty in cirrhosis.
The glucagon/GLP-1 dual agonist is noninferior to placebo for major adverse cardiovascular events and lowers blood pressure and waist size.
Advertisement
Advertisement
Trending on AJMC
1
Survodutide Meets CV Safety End Point in SYNCHRONIZE-CVOT
2
Hepatitis B Functional Cure Persists Off Treatment After Bepirovirsen
3
Data Show Upadacitinib Repigments Skin in Nonsegmental Vitiligo
4
Oral Iberdomide May Widen Myeloma Access: Mateo Mejia Saldarriaga, MD
5